Robbins Farley Buys New Shares in Astrazeneca Plc $AZN

Robbins Farley bought a new position in shares of Astrazeneca Plc (NYSE:AZN) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 25,635 shares of the company’s stock, valued at approximately $4,861,000. Astrazeneca comprises approximately 1.9% of Robbins Farley’s holdings, making the stock its 25th largest position.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Amundi lifted its stake in shares of Astrazeneca by 146,574.4% during the 1st quarter. Amundi now owns 15,386,149 shares of the company’s stock worth $3,034,456,000 after buying an additional 15,375,659 shares during the last quarter. Janus Henderson Group PLC raised its holdings in Astrazeneca by 889.9% in the 1st quarter. Janus Henderson Group PLC now owns 11,949,424 shares of the company’s stock valued at $2,319,947,000 after acquiring an additional 10,742,268 shares during the period. Rathbones Group PLC lifted its position in Astrazeneca by 106,772.0% during the first quarter. Rathbones Group PLC now owns 8,054,943 shares of the company’s stock worth $1,560,419,000 after acquiring an additional 8,047,406 shares during the last quarter. Royal Bank of Canada boosted its holdings in shares of Astrazeneca by 208.6% during the first quarter. Royal Bank of Canada now owns 10,386,455 shares of the company’s stock worth $2,048,417,000 after acquiring an additional 7,021,126 shares during the period. Finally, Swiss National Bank acquired a new position in shares of Astrazeneca in the first quarter valued at approximately $1,202,714,000. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Price Performance

AZN stock opened at $161.74 on Thursday. The company’s 50-day moving average price is $170.15 and its two-hundred day moving average price is $184.24. The firm has a market cap of $250.85 billion, a P/E ratio of 24.18, a P/E/G ratio of 1.27 and a beta of 0.25. The company has a quick ratio of 0.67, a current ratio of 0.89 and a debt-to-equity ratio of 0.47. Astrazeneca Plc has a 12 month low of $145.79 and a 12 month high of $212.71.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Monday, July 27th. The company reported $2.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.13. The business had revenue of $15.38 billion for the quarter, compared to analyst estimates of $15.44 billion. Astrazeneca had a net margin of 17.02% and a return on equity of 31.45%. The firm’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter last year, the business posted $2.17 EPS. On average, analysts anticipate that Astrazeneca Plc will post 10.19 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Barclays reissued a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. CICC Research assumed coverage on Astrazeneca in a research report on Sunday, August 23rd. They set an “outperform” rating and a $198.00 price objective on the stock. Bank of America reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday, July 1st. Wall Street Zen cut shares of Astrazeneca from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, HSBC lowered shares of Astrazeneca from a “buy” rating to a “hold” rating in a research report on Monday, July 13th. Thirteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $206.67.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.